empagliflozin/linagliptin vs linagliptin
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of empagliflozin/linagliptin and linagliptin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Inducers of P-glycoprotein or CYP3A4 Enzymes Clinical Impact Rifampin decreased linagliptin exposure, suggesting that the efficacy of linagliptin may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Intervention Use of alternative treatments is strongly recommended when linagliptin is to be administered with a strong P-gp or CYP3A4 inducer.
Glyxambi
Tradjenta
Glyxambi is a drug that combines three medicines to help lower blood sugar in adults with type 2 diabetes. It can also lower the risk of death from heart problems in those with both type 2 diabetes and heart disease.
No summary available.
Glyxambi is used to improve blood sugar control in adults with type 2 diabetes. It should be used along with diet and exercise. Glyxambi can also help lower the risk of death caused by heart problems if you have both type 2 diabetes and heart disease. It is not for people with type 1 diabetes.
Information not available.
Glyxambi works in three ways to lower blood sugar. Empagliflozin helps your kidneys remove sugar from your blood through urine. Linagliptin helps your body release more insulin after meals. Metformin helps to decrease the amount of sugar your liver makes and helps your body use insulin better.
Information not available.
- • Upper respiratory infection (like a cold)
- • Urinary tract infection
- • Runny or stuffy nose
- • Diarrhea
- • Constipation
- • Runny nose or sore throat
- • Diarrhea
- Increased blood sugar 146
- Diabetic ketoacidosis 144
- Feeling sick to your stomach 102
- Fungal infection 92
- Weight loss 86
- Blood Glucose Increased 1,326
- Diarrhoea 1,196
- Nausea 1,138
- Fatigue 1,028
- Dyspnoea 998
Glyxambi contains metformin, which can cause a serious side effect called lactic acidosis. Lactic acidosis is a buildup of lactic acid in the blood. It can be life-threatening. Get medical help right away if you have symptoms like feeling very weak, tired, or uncomfortable; unusual muscle pain; trouble breathing; stomach pain with nausea and vomiting; feeling cold, especially in your arms and legs; feeling dizzy or lightheaded; or a sudden change in your heartbeat.
No specific warnings noted.
Glyxambi is not recommended during the second and third trimesters of pregnancy due to potential harm to the baby's kidneys. It is also not recommended while breastfeeding. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
No pregnancy information available.
Also Compare, Nearby Drugs
Compare linagliptin with
How to Read This empagliflozin/linagliptin vs linagliptin Comparison
empagliflozin/linagliptin is classified in the SGLT2 / DPP-4 Combination drug class, while linagliptin sits within the DPP-4 Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, empagliflozin/linagliptin has 570 submissions while linagliptin has 5,686. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to some drugs make your body process linagliptin too quickly, which can make the medication less effective at lowering your blood sugar.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for empagliflozin/linagliptin or linagliptin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.